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Abstract
Mycobacterium tuberculosis harbours little DNA sequence diversity compared with other bacteria. However, there is mounting evidence
that strain-to-strain variation in this organism has been underestimated. We review our current understanding of the genetic diversity
among M. tuberculosis clinical strains and discuss the relevance of this diversity for the ongoing global epidemics of drug-resistant tuber-
culosis. Based on ﬁndings in other bacteria, we propose that epistatic interactions between pre-existing differences in strain genetic
background, acquired drug-resistance-conferring mutations and compensatory changes could play a role in the emergence and spread of
drug-resistant M. tuberculosis.
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Introduction
Tuberculosis (TB) remains an important global health prob-
lem, with close to 10 million new cases per year and a pool
of 2 billion latently infected individuals worldwide [1]. Of
particular concern are the ongoing epidemics of multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB
(XDR-TB), which threaten to make TB incurable [2]. Tuber-
culosis is a complex phenomenon driven by multiple biologi-
cal, socioeconomic and environmental factors [3]. In this
review, we discuss some of the bacteriological factors
involved in TB with a particular focus on drug resistance.
We start by reviewing our current knowledge of the genetic
diversity in the Mycobacterium tuberculosis complex (MTBC),
the causative agent of human TB, and how this diversity
inﬂuences the emergence of drug-resistant strains. We then
summarize some recent ﬁndings from other bacteria on the
role of epistasis in the evolution of drug resistance, and end
by discussing possible implications for our understanding of
MDR-TB and XDR-TB.
Strain Diversity in MTBC
Despite exhibiting limited DNA sequence diversity compared
with other bacteria [4], the extent of strain diversity in
MTBC is more pronounced than previously believed [5].
Recent comparative genomic studies have shown that geno-
mic deletions and duplications represent an important source
of genomic plasticity in MTBC [6–13]. Furthermore, investi-
gation of global collections of clinical strains revealed that
human MTBC exhibits a phylogeographic population struc-
ture with different strain lineages associated with particular
geographic regions and human populations [6,14–18]. In a
study by Hershberg et al. [19], 89 genes were sequenced in
each of 108 strains representative of the global diversity of
MTBC. Based on these gene sequences, the authors con-
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structed the most comprehensive DNA sequence-based phy-
logeny of MTBC to date [20]. The authors also showed that
the genetic distances between the most distant human
MTBC strains were equivalent to the genetic distance
between an average human strain and animal-adapted MTBC
[19]. Because animal-adapted MTBC such as Mycobacterium
bovis and Mycobacterium microti are believed to form distinct
ecotypes within MTBC [21], the ﬁndings by Hershberg et al.
[19] support the notion that the different human-adapted lin-
eages of MTBC might represent different ecotypes adapted
to different human populations [6,18]. In 2010, Comas et al.
[22] used 21 whole genome sequences to generate the ﬁrst
whole genome-based phylogeny of human-adapted MTBC.
This phylogeny conﬁrmed that human-adapted MTBC con-
sists of six main phylogenetic lineages, two of which are also
known as M. africanum [23].
DNA sequencing studies in MTBC clinical isolates found
consistently that two-thirds of the single nucleotide polymor-
phisms in MTBC were non-synonymous [19,22,24]. Further-
more, the study by Hershberg et al. [19] showed that about
40% of these non-synonymous single nucleotide polymor-
phisms occurred at positions that were highly conserved in
other mycobacteria, and therefore were likely to affect gene
function. The authors concluded that purifying selection
against non-synonymous single nucleotide polymorphisms
was reduced in MTBC. Despite this high proportion of non-
synonymous single nucleotide polymorphisms in MTBC, the
study by Comas et al. [22] found that essential genes were
more evolutionarily conserved than non-essential genes.
Hence, even though purifying selection in MTBC might be
reduced compared with other bacteria [19], natural selection
is still acting on MTBC and differentiating between various
gene classes [22].
The studies reviewed here show that strain genetic diver-
sity in MTBC includes genomic insertions/deletions and
duplications, as well as non-synonymous single nucleotide
polymorphisms, many of which are predicted to have func-
tional effects. An important question is how this genetic
diversity translates into phenotypic diversity. A recent
review compiled the results of 100 published studies that
evaluated the effect of MTBC strain diversity on experimen-
tal and clinical phenotypes [25]. Based on this review, one
concludes that clinical strains of MTBC differ in immunoge-
nicity and virulence in infection models. However, the role
of strain diversity in clinical settings is less clear. One of the
difﬁculties when studying the impact of strain diversity in
patient populations is that many additional variables need to
be taken into account [3]. Furthermore, strain classiﬁcation
for MTBC remains an issue as no universally accepted stan-
dard has been deﬁned. Such a new standard is urgently
needed and should be based on whole genome sequencing
[26].
In addition to the possible impact of strain variation on
the outcome of TB infection and disease, this diversity is rel-
evant for our understanding of drug resistance. For example,
the so-called ‘Beijing’ family of strains has been associated
with drug resistance in multiple reports (reviewed in [27]).
However, the underlying cause of this association remains
unknown, even though multiple hypotheses have been put
forward. One thought is that the genetic background of Beij-
ing strains might predispose to the acquisition of mutations
that confer drug resistance [28]. However, evidence for an
increased mutation rate in Beijing strains is still lacking [29].
Before discussing other possible effects of MTBC diversity
on drug resistance, let us brieﬂy review some of the most
important features of the current epidemic of drug-resistant
TB.
Factors Driving MDR/XDR-TB
The past 20 years have seen the worldwide appearance of
MDR-TB, followed by XDR-TB [2], and, most recently,
strains that are resistant to all antituberculosis drugs, the so-
called ‘totally drug-resistant’ or TDR strains [30]. MDR-TB is
caused by MTBC that is resistant to at least isoniazid and rif-
ampicin, the most important ﬁrst-line drugs against TB [2].
XDR-TB is caused by MDR strains with additional resistance
to any ﬂuoroquinolone and one of the three injectable drugs,
capreomycin, kanamycin and amikacin. MTBC acquires MDR
and XDR through a stepwise accumulation of chromosomal
mutations. In most cases, each of these mutations confers
resistance to an individual drug [31].
Drug resistance in MTBC can be acquired de novo in indi-
vidual patients undergoing TB treatment, either because of
lack of patient adherence or through an interrupted drug
supply. Alternatively, drug-resistant strains can spread
through direct transmission of MTBC strains that are already
drug-resistant. In addition, treatment for other diseases can
also contribute to acquired resistance in TB. For instance,
widespread use of ﬂuoroquinolones for respiratory tract and
other infections might drive resistance to ﬂuoroquinolones
in TB [32]. Given the ﬁnancial burden and logistical difﬁcul-
ties associated with treating MDR-TB and XDR-TB [2], it is
important to understand the evolutionary mechanisms that
promote the emergence of highly drug-resistant MTBC.
Mathematical models predict that one of the most impor-
tant factors inﬂuencing the future of MDR/XDR-TB is the
relative ﬁtness of drug-resistant strains compared with drug-
susceptible strains [33–35]. As in other bacteria [36], resis-
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tance-conferring mutations are often associated with a ﬁtness
‘cost’ in MTBC [37–39]. However, this ﬁtness cost varies
depending on the speciﬁc drug-resistance-conferring muta-
tions, and mutations associated with no ﬁtness cost have also
been described [37–41]. Furthermore, the strain genetic
background in which a speciﬁc resistance-conferring muta-
tion occurs can modulate the ﬁtness impact of this mutation
[37]. In clinical settings, there seems to be a strong selection
for low- or no-ﬁtness cost mutations [37,38,40–42]. How-
ever, data on the relative transmissibility of MDR strains
compared with drug-susceptible strains are inconsistent
(reviewed in [27]), suggesting that the ﬁtness of drug-resis-
tant strains is heterogeneous [33]. Both MDR-TB and XDR-
TB are often associated with human immunodeﬁciency virus
(HIV) co-infection, indicating that drug-resistant strains might
be less ﬁt than fully susceptible strains [27]. However, in
some areas of the world, such as the countries of the for-
mer Soviet Union where the prevalence of MDR is particu-
larly high, MDR strains of MTBC are highly successful,
despite low rates of HIV [1]. One possibility is that because
MDR strains have been circulating for a long time in these
areas, compensatory evolution has occurred [43], which alle-
viated initial ﬁtness deﬁcits. Interestingly, these regions are
also where the Beijing family of strains has been associated
most frequently with drug resistance (reviewed in [27]), sug-
gesting that the strain genetic background may also play a
role.
Another question is how the effects of different drug-
resistance-conferring mutations inﬂuence each other. Is it
that with each additional mutation a strain will become less
and less ﬁt, and we therefore need not worry about the
transmission of highly drug-resistant strains? Despite the
importance of ﬁtness cost in the evolution of drug resis-
tance, no study has addressed this question in MTBC.
In summary, the emergence of drug resistance in MTBC
depends primarily on the initial acquisition of drug-resis-
tance-conferring mutations. However, the ﬁtness effects of
these mutations could be modulated by additional genetic
factors, including pre-existing differences in strain genetic
background, additional drug-resistance-conferring mutations,
and compensatory adaptations. The interactions between
these types of genetic changes are generally referred to as
epistasis (Fig. 1).
Epistasis in Drug-resistant Bacteria
Epistasis occurs when the phenotypic effect of a mutation
changes depending on the presence or absence of other
mutations in the same genome [44]. Interactions among
mutations can result in positive epistasis in the case of bene-
ﬁcial mutations and negative epistasis in the case of deleteri-
ous mutations. Although epistasis can impact any phenotype,
in this review, we will focus on the role of epistasis in drug-
resistant bacteria. Here, epistasis becomes manifest when a
particular drug-resistance-conferring mutation has a different
ﬁtness effect depending on the strain genetic background.
Several studies have observed this phenomenon in drug-
resistant bacteria [37,45,46]. Alternatively, when bacteria
carry multiple drug-resistance-conferring mutations, the
overall ﬁtness cost of resistance will depend on the cost
associated with each individual resistance mutation and on
the epistatic interactions between these resistance mutations
[47]. Positive epistasis occurs when the combined cost of
carrying multiple resistance mutations is less than what
would be expected if the mutations had independent and
simple additive effects on ﬁtness. Whereas positive epistasis
promotes the evolution of MDR by minimizing its cost, nega-
tive epistasis constrains the evolution of MDR by aggravating
its cost [47].
Epistatic interactions can also affect compensatory adap-
tation to the ﬁtness costs of resistance. Positive epistasis
can be caused by a compensatory mutation, when the
mutation mitigates the ﬁtness costs of a particular resis-
tance-conferring mutation but does not in itself contribute
to drug resistance [48]. Compensatory evolution has been
described in many drug-resistant bacteria (reviewed in
[43]). Importantly, several studies have found that when
compensatory mutations were placed into their respective
wild-type drug-susceptible strain backgrounds, they became
deleterious to strain ﬁtness, thereby demonstrating the
effect of epistasis [47,49,50]. These observations have
important implications for public health because once drug-
FIG. 1. Proposed epistatic interactions in drug-resistant Mycobacte-
rium tuberculosis complex (MTBC). Human-adapted MTBC consists of
six main phylogenetic lineages. The genetic background of these
strain lineages could interact differently with drug-resistance-confer-
ring mutations. Similar interactions could occur between different
drug-resistance-conferring mutations and compensatory mutations.
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resistant bacteria have acquired a compensatory mutation,
positive epistasis between the drug-resistance-conferring
mutation and the compensatory mutation will prevent the
loss of resistance, even if the corresponding antibiotic is
withdrawn [43].
Few studies have looked at epistatic interactions between
multiple drug-resistance-conferring mutations in bacteria. A
study in Pseudomonas aeruginosa showed that the cost of
streptomycin resistance was lower when the streptomycin-
resistance-conferring mutations were in a rifampicin-resistant
genetic background as opposed to an isogenic rifampicin-sus-
ceptible control background [51]. Similarly, Trindade et al.
[47] showed that in Escherichia coli, the cost of streptomycin
resistance could be compensated by various mutations con-
ferring resistance to rifampicin. In the remaining part of this
review, we will discuss some observations that might hint
towards possible epistatic interactions in drug-resistant
MTBC.
Signs of Epistasis in Drug-resistant MTBC
As mentioned above, the Beijing family of strains has repeat-
edly been associated with drug resistance [27]. This associa-
tion could reﬂect positive epistasis between the Beijing
genetic background and one or several drug-resistance-con-
ferring mutations. A study from San Francisco reported an
association between different phylogenetic lineages of MTBC
and particular isoniazid-resistance-conferring mutations [52].
Interestingly, some of these associations were independently
reported in a study from London [14]. Similarly, a study from
Ghana found differences between the frequencies of particu-
lar isoniazid-resistance-conferring mutations in M. africanum
compared with other MTBC lineages [53]. Taken together,
these data are consistent with possible epistatic interactions
between different isoniazid-resistance-conferring mutations
and pre-existing differences in the genetic backgrounds of
the different lineages of MTBC [19].
Little is known with respect to the interactions between
different drug-resistance-conferring mutations in MTBC. One
intriguing observation though is that the isoniazid-resistance-
conferring mutation katG S315T is associated with MDR-TB
[54]. KatG encodes a catalase–peroxidase that converts isoni-
azid into its bioactive form. However, this protein also pro-
tects MTBC against oxidative stress [55]. Clinical strains
with an inactivated KatG are highly resistant to isoniazid but
are also attenuated in virulence [56,57]. In contrast, katG
S315T has only a minimal effect on virulence and strain ﬁt-
ness [58]. If MDR clinical strains are selected to minimize
overall ﬁtness deﬁcits, low- or no-cost mutations like katG
S315T are expected to be over-represented in clinical set-
tings [59]. An alternative but not mutually exclusive explana-
tion is that the katG S315T mutation might interact in a
positive epistatic way with other drug-resistance-conferring
mutations. A study by Hazbon et al. [60] showed that labora-
tory-generated mutants with the embB306 mutation, usually
associated with resistance to ethambutol, had a growth
advantage under subminimal inhibitory concentrations of iso-
niazid and rifampicin. Therefore, the authors postulated that
embB306 might be involved in the acquisition of resistance
to isoniazid and rifampicin.
To date, only two papers have reported compensatory
mechanisms in drug-resistant MTBC. Sherman et al. [61]
described a putative compensatory mutation related to isoni-
azid resistance. They showed that MTBC strains with an
inactivated katG acquired promoter mutations of the alkyl
hydroperoxide reductase ahpC, leading to the over-expres-
sion of this protein. The authors concluded that over-
expression of ahpC might compensate for the lack of detoxi-
ﬁcation through an inactivated katG. Another study used the
model organism Mycobacterium smegmatis to investigate com-
pensatory evolution in aminoglycoside resistance in MTBC
[50]. Clinically acquired resistance to kanamycin and amikacin
in MTBC is mainly the result of point mutations in the 16S
rRNA. The change G1491U confers an intermediate-level of
resistance but is associated with a signiﬁcant ﬁtness cost in
M. smegmatis. Introduction of C1409A into the G1491U
mutant restored ﬁtness to wild-type levels while maintaining
resistance. Interestingly, C1409A/G1491U double mutants
are also found in MTBC clinical isolates, albeit at low fre-
quencies [50].
Conclusions
In summary, the extent of strain genetic diversity in MTBC is
more pronounced than was traditionally believed, which has
implications for the development of new TB diagnostics,
drugs and vaccines [5]. Although there is clear evidence that
this diversity impacts the host immune response and viru-
lence in infection models, more work is needed to demon-
strate consistent effects in clinical settings [25]. Furthermore,
there are reasons to believe that strain diversity also plays a
role in the global emergence of MDR-TB and XDR-TB. In
particular, epistatic interactions between different drug-resis-
tance-conferring mutations, the strain genetic background,
and compensatory mutations need to be studied in more
detail. Such studies will be necessary to make more accurate
predictions about the future trajectory of the global epidem-
ics of MDR-TB and XDR-TB.
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